Cayman Chemical

A 2-thio-dimethoxy naphthoquinone analog that blocks Snail binding to p53 and induces p53 expression in cancer cells in a K-Ras dependent manner.

The CysLTs, LTC4 and LTD4, are potent mediators of asthma and hypersensitivity. They induce bronchoconstriction, increase microvascular permeability, and are vasoconstrictors of coronary arteries. Their biological effects are transduced by a pair of GPCRs, CysLT1 and CysLT2. Zafirlukast is a potent,...

A potent activator of Nrf2-regulated activity, both in vitro (10 μM) and in mice (50 mg/kg).

A cell-permeable, quinolone-based fluorescent probe used as a zinc indicator (excitation 368 nm, emission 490 nm); used to monitor intracellular zinc fluxes associated with apoptosis.

A major epidermal chromophore for the immunosuppressive effects of UV radiation that is produced in mammalian stratum corneum by the action of L-histidine ammonia lyase on histidine.

A synthetic analog of natural PtdIns featuring C16:0 fatty acids at the sn-1 and sn-2 positions; contains the same inositol and DAG stereochemistry as the natural compound.

A synthetic derivative of native coelenterazine that exhibits 16-fold higher luminescence intensity (emission maximum ~466 nm; half-total time of 0.6-1.2 sec) than native coelenterazine.

Antigen: Human GPR35 amino acids 295-304 Host: rabbit Species Reactivity: (+) Human, mouse, and porcine GPR35 Application(s): IHC (paraffin-embedded tissue) and WB GPR35 ligands include kynurenic acid and zaprinast. Multiple isoforms of this receptor have been reported and GPR35 mRNAs were detected...

Source: Highly purified mixture of human core histones (H2A, H2B, H3, and H4) isolated via hydroxyapatite chromatography from HeLa S3 (human cervical adenocarcinoma) nuclear pellet

An internal standard for the quantification of 5-OAHSA by GC- or LC-MS.

A synthetic intermediate for pharmaceutical synthesis.

A second generation antihistamine that acts as a selective histamine H1 receptor antagonist (pKi = 8).

A phospholipid containing the unsaturated long-chain (18:1) oleic acid inserted at the sn-1 and sn-2 positions; commonly used alone, or with other components, in the generation of micelles, liposomes, and other types of artificial membranes.

A derivative of EPA derived via epoxidation of the 17,18-double bond of EPA; a potent and selective activator of BK-type calcium-activated potassium ion channels in vascular smooth muscle cells.

An orally available inhibitor of microtubule polymerization (IC₅₀ = ~3 µM) that blocks cell cycling at the G2-M phase, which leads to cell death; cytotoxic to a range of cancer cell lines (IC₅₀s = 9-101 nM) and demonstrates antivascular activity in tumors both in vitro...

Source: Active recombinant C-terminal His-tag expressed in E. coli MW: 45.3 kDa HDAC8 is a Class I HDAC that catalyzes the deacetylation of core histones, resulting in tightening of nucleosomal integrity, restricting access to transcription factors, and suppression of transcription. It can also play...

Source: recombinant C-terminal histidine-tagged protein expressed using a baculovirus overexpression system in Sf21 cells Mr: 98.8 kDa A secreted lysophospholipase D that catalyzes the hydrolysis of LPC to generate LPA; ATX-LPA signaling is involved in a range of pathologies including tumor...

A long-chain ω-3 fatty acid with a hydroxyethylamide group attached at the alpha chain.

A widely distributed primary PG occuring in many species; causes contraction of vascular, bronchial, intestinal, and myometrial smooth muscle, and also exhibits potent luteolytic activity.

A novel analog of 17-phenyl trinor PGF2α ethyl amide.

An antagonist of OX2R (pKi = 7.5) that exhibits >250-fold selectivity for hOX2R compared with OX1R (IC₅₀s = 40 nM and >10,000 nM, respectively.

Potent, orally active CysLT receptor antagonist with KB values of 0.07 and 0.34 µM on guinea pig ileum and parenchyma, respectively.

(S)-(+)-2-hydroxy-3-Methylbutyric acid is a synthetic intermediate useful for pharmaceutical synthesis.

A pyrazine benzamide that prevents activation of all three isoforms of PKD in endothelial cells treated with VEGF (IC₅₀s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively); decreases VEGF-induced endothelial migration, proliferation, and tubulogenesis.